4.6 Review

Retinal vein thrombosis: The Internist's role in the etiologic and therapeutic management

Journal

THROMBOSIS RESEARCH
Volume 148, Issue -, Pages 118-124

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2016.11.004

Keywords

Retinal vein occlusion; Pathophysiology; Treatment; Anticoagulation

Funding

  1. Pfizer
  2. Leo Pharma
  3. Bayer
  4. Daiichi-Sankyo
  5. Novartis
  6. Celgene
  7. Alexion Pharmaceuticals

Ask authors/readers for more resources

Retinal vein occlusion is a common and important cause of vision loss. In general, knowledge about this condition is scant within an internist's practice but the condition is relevant because of its association with other chronic ailments. A diagnosis of RVO should prompt the investigation of conditions needing chronic management in these patients. In this review we summarize the clinical presentation of RVO, its classification, associated risk factors, and treatment focused in the internist's scope of practice. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available